ENP103: Type 1 Diabetes: Immunotherapies and Early Detection
About this episode
This episode discusses immunotherapies and early detection for Type 1 Diabetes with expert Desmond Schatz.
Recently the Endocrine Society held its 12th annual Type 1 Diabetes Fellows Series program, which combines comprehensive education on type 1 diabetes with career development opportunities to build knowledge, practical skills, and a lasting network of colleagues. For this episode, host Aaron Lohr talks with Desmond Schatz, MD , medical director of the Diabetes Institute and director of the Clinical Research Center at the University of Florida. Dr. Schatz gave a talk at the fellows series program titled, “Immunotherapies for Type 1 Diabetes: Need for Early Detection and Screening.” This year’s fellows series program and this episode were made possible by the support of Abbott Diabetes Care, CeQur Corp., Dexcom Inc., Insulet Corp., Breakthrough T1D (formerly the Juvenile Diabetes Research Foundation), Lilly USA, Mankind Pharma Limited, Medtronic Inc., Novo Nordisk Inc., and Vertex Pharmaceuticals Inc. Show notes are available at https://www.endocrine.org/podcast/enp103 — for helpful links or to hear more podcast episodes, visit https://www.endocrine.org/podcast
Sponsors
Abbott Diabetes Care, CeQur Corp., Dexcom Inc., Insulet Corp., Breakthrough T1D, Lilly USA, Mankind Pharma Limited, Medtronic Inc., Novo Nordisk Inc., Vertex Pharmaceuticals Inc.
More episodes of Endocrine News Podcast
- ENP111: Addressing the Endocrine Workforce Shortage
- ENP110: Hypercortisolism and T2D
- ENP109: Anti-Obesity Medications (CME credit available)
- ENP108: AI and Robotics in Surgery
- ENP107: Compounded Obesity Medications
- ENP106: Reversing Bariatric Surgery
Explore listener stats, chart rankings, contacts and more on the Endocrine News Podcast podcast page.